CA2992419A1 - Combinaisons de peptides a utiliser pour le diagnostic de la schizophrenie - Google Patents
Combinaisons de peptides a utiliser pour le diagnostic de la schizophrenie Download PDFInfo
- Publication number
- CA2992419A1 CA2992419A1 CA2992419A CA2992419A CA2992419A1 CA 2992419 A1 CA2992419 A1 CA 2992419A1 CA 2992419 A CA2992419 A CA 2992419A CA 2992419 A CA2992419 A CA 2992419A CA 2992419 A1 CA2992419 A1 CA 2992419A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- chy
- amino acid
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000000980 schizophrenia Diseases 0.000 title claims description 34
- 238000003745 diagnosis Methods 0.000 title claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 230000000698 schizophrenic effect Effects 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims description 74
- 150000001413 amino acids Chemical class 0.000 claims description 58
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000539 dimer Substances 0.000 abstract description 22
- 235000001014 amino acid Nutrition 0.000 description 54
- 208000027691 Conduct disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 229960004170 clozapine Drugs 0.000 description 10
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 208000036626 Mental retardation Diseases 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000002228 disulfide group Chemical group 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 208000024823 antisocial personality disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000000612 dual polarization interferometry Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- 238000001768 microscale thermophoresis Methods 0.000 description 2
- 229940054010 other antipsychotics in atc Drugs 0.000 description 2
- 238000010384 proximity ligation assay Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne, d'une manière générale, une composition comprenant une combinaison d'au moins un peptide court et d'au moins un peptide dimère, selon un rapport défini, auxquels se lient des auto-anticorps présents à des taux élevés chez les patients schizophrènes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192206P | 2015-07-14 | 2015-07-14 | |
| US62/192,206 | 2015-07-14 | ||
| PCT/IL2016/050768 WO2017009846A1 (fr) | 2015-07-14 | 2016-07-14 | Combinaisons de peptides à utiliser pour le diagnostic de la schizophrénie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2992419A1 true CA2992419A1 (fr) | 2017-01-19 |
| CA2992419C CA2992419C (fr) | 2023-08-15 |
Family
ID=56561396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2992419A Active CA2992419C (fr) | 2015-07-14 | 2016-07-14 | Combinaisons de peptides a utiliser pour le diagnostic de la schizophrenie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11385242B2 (fr) |
| EP (1) | EP3322989B1 (fr) |
| JP (1) | JP2018524595A (fr) |
| CA (1) | CA2992419C (fr) |
| ES (1) | ES3038398T3 (fr) |
| IL (1) | IL256880B2 (fr) |
| WO (1) | WO2017009846A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122490A0 (en) * | 1997-12-07 | 1998-06-15 | Yeda Res & Dev | Assay for schizophrenia based on skin reaction |
| US7098304B1 (en) * | 1998-04-02 | 2006-08-29 | Yeda Research And Development Co. Ltd. | Assay for the diagnosis of schizophrenia based on a new peptide |
| DE69919701T2 (de) * | 1998-06-01 | 2005-09-15 | Genentech, Inc., South San Francisco | Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie |
| CA2441925C (fr) | 2001-03-21 | 2012-07-31 | Yeda Research And Development Co. Ltd. | Nouveaux peptides permettant le diagnostic de la schizophrenie |
| ES2332590T3 (es) * | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| US20130005645A1 (en) * | 2010-01-06 | 2013-01-03 | Vitek Michael P | Apoe peptide dimers and uses thereof |
| US20120259092A1 (en) * | 2011-04-11 | 2012-10-11 | David Chatenet | Npy antagonists |
| KR20130057012A (ko) * | 2011-11-23 | 2013-05-31 | 대진대학교 산학협력단 | 면역세포 억제용 조성물 |
| JPWO2015019979A1 (ja) * | 2013-08-05 | 2017-03-02 | 国立研究開発法人国立精神・神経医療研究センター | 統合失調症に関するバイオマーカー |
-
2016
- 2016-07-14 WO PCT/IL2016/050768 patent/WO2017009846A1/fr not_active Ceased
- 2016-07-14 IL IL256880A patent/IL256880B2/en unknown
- 2016-07-14 ES ES16745856T patent/ES3038398T3/es active Active
- 2016-07-14 EP EP16745856.1A patent/EP3322989B1/fr active Active
- 2016-07-14 US US15/744,532 patent/US11385242B2/en active Active
- 2016-07-14 CA CA2992419A patent/CA2992419C/fr active Active
- 2016-07-14 JP JP2018501151A patent/JP2018524595A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL256880B1 (en) | 2023-11-01 |
| IL256880B2 (en) | 2024-03-01 |
| IL256880A (en) | 2018-03-29 |
| EP3322989B1 (fr) | 2025-06-04 |
| WO2017009846A1 (fr) | 2017-01-19 |
| US11385242B2 (en) | 2022-07-12 |
| US20180348234A1 (en) | 2018-12-06 |
| ES3038398T3 (en) | 2025-10-13 |
| JP2018524595A (ja) | 2018-08-30 |
| EP3322989A1 (fr) | 2018-05-23 |
| CA2992419C (fr) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kasper et al. | A calreticulin‐like molecule from the human hookworm Necator americanus interacts with C1q and the cytoplasmic signalling domains of some integrins | |
| KR20130043088A (ko) | 면역검정 표준물 및 검정내 보정 표준물을 사용한 임상 바이오마커의 측정 | |
| US9896485B2 (en) | Nanopore sensors and uses thereof | |
| CN112469832A (zh) | 蛋白质上的翻译后修饰的单分子测序鉴别 | |
| Walker | ncd and kinesin motor domains interact with both alpha-and beta-tubulin. | |
| JP2011505390A (ja) | リウマチ性関節炎自己抗体との免疫反応性合成ペプチド | |
| CA2992419C (fr) | Combinaisons de peptides a utiliser pour le diagnostic de la schizophrenie | |
| EP3562841A1 (fr) | Nouvel anticorps monoclonal spécifique de la biotine, et son utilisation | |
| KR20160132292A (ko) | Cd133 검출용 다중 펩타이드 프로브 | |
| JP2008255046A (ja) | 融合タンパク質、これを用いた抗体捕捉担体および抗原検出法 | |
| KR102734614B1 (ko) | 카스파제-3 검출용 신규한 펩타이드 | |
| CN107255713B (zh) | 可用于诊断人肠道病毒感染的试剂盒 | |
| WO2006004332A1 (fr) | Dosage immunologique pour plasmodium falciparum et dispositif de dosage utilise a cette fin | |
| CN108663523A (zh) | 可用于诊断人肠道病毒71型感染的试剂盒 | |
| KR102789819B1 (ko) | 트롬빈 검출용 신규한 펩타이드 및 이의 용도 | |
| KR102734588B1 (ko) | 트롬빈 검출용 신규한 펩타이드 | |
| JP2021099291A (ja) | 細胞外小胞の検出方法および細胞外小胞の検出キット | |
| KR102880493B1 (ko) | 베타-락토글로불린 검출용 신규한 펩타이드 | |
| KR102882547B1 (ko) | 인터루킨 1 베타 검출용 신규한 펩타이드 | |
| CN105652009B (zh) | 可用于辅助诊断疟疾的试剂盒 | |
| KR102756208B1 (ko) | 카뎁신 b 검출용 펩타이드 | |
| KR102759471B1 (ko) | 오보뮤코이드에 특이적으로 결합하는 펩타이드 및 이의 용도 | |
| Kim et al. | Fluorescence detection of protein/Z-DNA interactions | |
| US8673309B2 (en) | Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 | |
| CA2441925C (fr) | Nouveaux peptides permettant le diagnostic de la schizophrenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210714 |
|
| EEER | Examination request |
Effective date: 20210714 |
|
| EEER | Examination request |
Effective date: 20210714 |
|
| EEER | Examination request |
Effective date: 20210714 |
|
| EEER | Examination request |
Effective date: 20210714 |
|
| EEER | Examination request |
Effective date: 20210714 |